CMS to enter negotiations with drugmakers over the price of four cancer medications

FDA and CMS announce RAPID coverage pathway aimed at accelerating patient access to some Breakthrough medical devices

The Centers for Medicare and Medicaid Services and FDA announced a new coverage pathway—called the Regulatory Alignment for Predictable and Immediate Device, or RAPID pathway—designed to expedite access to certain FDA-designated Class II and Class III Breakthrough devices for people with Medicare.

April 24, 2026

Vol.52 No.16

Cancer Policy

CMS proposed rule would implement electronic prior authorization requirements for covered drugs in federal health plans

The Centers for Medicare & Medicaid Services issued the 2026 CMS Interoperability Standards and Prior Authorization for Drugs proposed rule, which aims to shorten care delays and improve transparency within federal health insurance programs by establishing electronic prior authorization, or ePA, requirements for covered prescription drugs and expedite federal response deadlines to ensure patients receive life-critical medications without administrative delay.

CMS proposes rule to update Medicare payments and transparency requirements for hospice care

The Centers for Medicare & Medicaid Services has proposed a rule to update Medicare payments for hospice care in the next fiscal year, which begins on Oct. 1.

PanTracer LBx liquid biopsy profiling test receives Medicare coverage

NeoGenomics announced the PanTracer LBx test has received coverage from CMS’ Molecular Diagnostics Services Program under Local Coverage Determination - MolDX: Plasma-Based Genomic Profiling in Solid Tumors.

March 20, 2026

Vol.52 No.11

Podcast

With five-year cancer survival at an all-time high, does this mean people are living longer?

“It's really, really important that every year since 1991, cancer mortality has dropped by a little bit, and it did again!” said Paul Goldberg, editor and publisher of The Cancer Letter. “Now, mortality is a good metric, age-adjusted mortality. As far as survival, well, that's not so good.”

January 21, 2026

Clinical Health Equity

New Medicaid work requirements could lead to 1.6 million missed cancer screenings over two years

New Medicaid work requirements included in President Donald Trump’s “One Big Beautiful Bill Act” could result in as many as 1.6 million missed screenings for breast, colon, and lung cancers within the first two years, researchers at the University of Chicago reported in a paper published in JAMA Oncology earlier this month.

January 16, 2026

Vol.52 No.02

By Sara Willa Ernst

CMS to enter negotiations with drugmakers over the price of four cancer medications

YOU MAY BE INTERESTED IN

FDA and CMS announce RAPID coverage pathway aimed at accelerating patient access to some Breakthrough medical devices

CMS proposed rule would implement electronic prior authorization requirements for covered drugs in federal health plans

CMS proposes rule to update Medicare payments and transparency requirements for hospice care

PanTracer LBx liquid biopsy profiling test receives Medicare coverage

With five-year cancer survival at an all-time high, does this mean people are living longer?

New Medicaid work requirements could lead to 1.6 million missed cancer screenings over two years

Renew today!

Subscriber content

Never miss an issue!

Login